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Abstract
Background: Angiogenesis, the formation of new blood vessels from existing vasculature, plays an essential role in tumor
growth, invasion, and metastasis. 16K hPRL, the antiangiogenic 16-kDa N-terminal fragment of human prolactin was shown
to prevent tumor growth and metastasis by modifying tumor vessel morphology.
Methodology/Principal Findings: Here we investigated the effect of 16K hPRL on tumor vessel maturation and on the
related signaling pathways. We show that 16K hPRL treatment leads, in a murine B16-F10 tumor model, to a dysfunctional
tumor vasculature with reduced pericyte coverage, and disruption of the PDGF-B/PDGFR-B, Ang/Tie2, and Delta/Notch
pathways. In an aortic ring assay, 16K hPRL impairs endothelial cell and pericyte outgrowth from the vascular ring. In
addition, 16K hPRL prevents pericyte migration to endothelial cells. This event was independent of a direct inhibitory effect
of 16K hPRL on pericyte viability, proliferation, or migration. In endothelial cell-pericyte cocultures, we found 16K hPRL to
disturb Notch signaling.
Conclusions/Significance: Taken together, our data show that 16K hPRL impairs functional tumor neovascularization by
inhibiting vessel maturation and for the first time that an endogenous antiangiogenic agent disturbs Notch signaling. These
findings provide new insights into the mechanisms of 16K hPRL action and highlight its potential for use in anticancer
therapy.
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Introduction
Angiogenesis is a crucial step in many pathologies including
tumor growth and metastasis [1]. Antiangiogenic therapy is thus
considered as an important option for the treatment of cancer.
The 16-kDa N-terminal fragment of human prolactin (16K hPRL)
has been shown to impair angiogenesis both in vitro and in vivo. In
particular, 16K hPRL inhibits the proliferation of endothelial cells
[2,3] (both basal and stimulated by basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor (VEGF)) by
blocking endothelial cell cycle in the G0–G1 and G2-M transitions
through combined effects on positive and negative regulators of
cell cycle progression: it down regulates cyclin-D1 and cyclin-B1
and up regulates p21cip1 and p27kip1 [4]. It has been also
demonstrated that 16K hPRL induces endothelial cell apoptosis by
activating Caspase-3 and NF-kB [5,6]. NF-kB is necessary for
activation of Caspase-8 and -9, which in turn trigger Caspase-3
activation and DNA fragmentation [6]. In addition, 16K
hPRL inhibits endothelial cell migration by downregulating the
Ras-Tiam1-Rac1-Pak1 signaling pathway [7]. The antiangiogenic
activity of 16K hPRL appears to be mediated by a saturable high-
affinity binding site distinct from the PRL receptor [8]. In vivo,
excess of 16K hPRL has been shown to mediate human
postpartum cardiomyopathy (PPCM) [9]. Treatment with bromo-
criptine, an inhibitior of prolactin secretion, prevents the
development of PPCM in mice, whereas forced myocardial
generation of 16K hPRL impairs the cardiac capillary network
and function, thereby recapitulating the cardiac phenotype of
PPCM. Finally, 16K hPRL has been shown to inhibit angiogenesis
in a mouse retinopathy model [10], and to prevent tumor growth
and metastasis establishment in various mouse models
[11,12,13,14]. Tumors of 16K hPRL-treated mice are character-
ized by an increased number of vessels that are, however, smaller
and narrower [13,14]. In addition, in tumor tissues a higher
expression of adhesion molecules (ICAM-1, VCAM-1, or E-
selectin) in endothelial cells and a significantly higher number of
infiltrated leucocytes is observed within the tumor treated with
16K hPRL compared with the untreated ones [15].
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The maturation of new vasculature requires pericyte recruit-
ment, generation of an extracellular matrix, and specialization of
the vessel wall for structural support and regulation of vessel
function. These processes are orchestrated by a constellation of
ligands and receptors on pericytes and endothelial cells, whose
spatio-temporal patterns of expression and concentration are
tightly regulated. Inappropriate levels of these molecules produce
an abnormal vasculature, a hallmark of various pathologies [16].
Several signaling pathways, such as the PDGF-B/PDGFR-B,
Ang/Tie2, TGF-b, sphingosine-1-phosphate (S1P), Notch, and
EphrinB2 pathways, have been associated with pericyte recruitment
and heterotypic communication between endothelial cells and
pericytes [17]. PDGF-B is secreted by endothelial cells to attract
comigrating pericytes expressing its receptor, PDGFR-B. It also
stimulates proliferation of vascular smoothmuscle cells and induces a
mural cell fate in undifferentiated mesenchymal cells [16,18,19].
Ang1 expressed by mural cells binds to and activates the Tie2
receptor on endothelial cells. Consequently, angiogenesis is
stimulated by increased endothelial cell survival and subsequent
mural cell attachment. The role of Ang1 in tumor-associated
angiogenesis remains controversial and depends on the tumor cell
type and/or the dosage of Ang2 in the tumors [20]. The role of Ang2
appears to be contextual. In the absence of VEGF, endothelium-
derived Ang2 is an antagonistic ligand of Tie2, causing endothelial
cell death and defective maturation. Ang2 expression appears to be
negatively correlated with pericyte coverage in both spontaneous
and experimental tumor models [16,18,19,21]. In contrast to the
PDGF-B/PDGFR-B and Ang/Tie2 signaling pathways allowing
cell-contact-independent endothelial/mural cell crosstalk, the Notch
and EphrinB2 signaling pathways require direct endothelial cell-
mural cell contact. Notch receptors (Notch1 to 4), their ligands
(Delta-like and Jagged), and their downstream mediators (Hes/Hey)
are highly expressed, in different combinations, in both endothelial
cells and mural cells. Notch3, the predominant Notch receptor in
vascular smooth muscle cells, can be activated in endothelial cells by
Dll1 and Jagged1, thereby promoting mural cell maturation
[22,23,24]. Evidence of increased Dll4 expression in the tumor
endothelium correlates with tumor vessel maturation and remodel-
ing [25,26]. EphrinB2, a ligand of Eph receptor tyrosine kinases, has
recently been characterized as a key mediator in the assembly of
vascular structures by endothelial and mural cells [27,28]. By
interacting with Notch4, Dll4 can upregulate the expression of
EphrinB2 in endothelial cells under both physiological and
pathological conditions [25,29].
As stated above, tumor growth suppression by 16K hPRL is
accompanied by an increased tumor vessel density and the
appearance of small and narrow, collapsed capillaries. This
specific phenotype led us to hypothesize that 16K hPRL might
prevent the development of a functional tumor vasculature by
affecting vessel maturation. Here, we provide evidence in favor of
this hypothesis. We demonstrate, firstly, that in the murine B16-
F10 melanoma model, 16K hPRL treatment decreases tumor
perfusion and reduces pericyte coverage of tumor vessels. We
further describe ex vivo and in vitro experiments showing that 16K
hPRL does not affect pericytes directly but causes defective
pericyte recruitment to endothelial cells with disruption of the
PDGF-B, Ang, and Notch pathways.
Results
16K hPRL reduces vessel perfusion and pericyte coverage
of tumor vasculature
In the murine subcutaneous B16F10 melanoma model, the
antiangiogenic 16K hPRL significantly reduced tumor growth by
about 50%, but increased the vessel density as previously shown
[13] (Figure 1A–B). These observations led us to hypothesize that
16K hPRL impairs the functionality of the tumor vascular network
rather than reducing vessel density. To test this hypothesis, we
examined the effect of 16K hPRL on tumor vessel perfusion by
comparing the distribution of intravascular lectin (used as a tracer
of perfused blood vessels) with that of CD31 (used to mark all
tumor vessels). We observed about 25% less perfusion in the
tumors of 16K-Ad-treated mice than in those of control mice
(Figure 1C–D). We wondered what might contribute to impairing
vascular function in the tumors of 16K-Ad-treated mice. Given the
small, narrow capillaries that characterize these tumors [13,14],
we hypothesized that 16K hPRL might prevent vessel maturation.
To test this hypothesis and because vessel maturation requires the
recruitment of pericytes, we first examined the mural cell coverage
of tumor vessels by immunohistochemical staining. Whatever
mural marker used (aSMA, desmin, or NG2), we observed a
significantly (20 to 40%) decreased coverage of CD31-positive
blood vessels by mural cells after 16K hPRL treatment (Figure 2A–
B). This effect of 16K hPRL was tumor-vessel specific, since we
detected no decrease in mural cell coverage and no reduction of
vessel perfusion in tracheal capillaries from the 16K-Ad-treated
mice (Figure 2C-D).
Next, we used qRT-PCR to measure the levels of transcripts of
two genes (Pdgfb and Ang1) encoding positive regulators and one
gene (Ang2) encoding a negative regulator of vessel maturation. In
tumors of Ad-16K treated mice, the levels of Pdgfb and Ang1
mRNAs were respectively 1.7-fold and 10-fold lower than in
tumors of control mice, whereas the level of Ang2 transcripts was 3-
fold higher (Figure 2E). We then used Western blotting to estimate
levels of Dll4, a Notch ligand known to be upregulated during
tumor angiogenesis [30,31], and EphrinB2, a downstream target
of Dll4. The levels of both proteins are reduced in the tumors of
Ad-16K treated mice (Figure 2F–G).
Together, these results support the view that 16K hPRL impairs
tumor vessel maturation in our mouse model.
16K hPRL inhibits pericyte outgrowth in an ex vivo
murine aortic ring assay
To further scrutinize the effects of 16K hPRL on vascular
maturation and morphogenesis, we used the murine aortic ring
assay. This assay measures the formation, from the aortic ring, of a
new network consisting of IB4-positive endothelial cells and NG2-
positive pericytes/smooth muscle cells (PC/SMC). Mouse aortic
ring explants were incubated with or without recombinant 16K
hPRL, and the angiogenic response was observed under bright
field microscopic examination (Figure 3A) and quantified by
computer-assisted image analysis for the length of the tube
(Figure 3B). In the presence of 16K hPRL, cellular network
formation was inhibited and fewer NG2-positive cells were
observed (Figure 3C). Thus, the antiangiogenic protein 16K
hPRL inhibits the outgrowth of a PC/SMC network.
16K hPRL inhibits pericyte recruitment by endothelial
cells in vitro
Next, we examined whether the observed inhibition of pericyte
network development by 16K hPRL might be due to defective
pericyte recruitment to endothelial cells. In an under-agarose
migration assay, we measured the ability of HBVP to migrate
towards HUVEC in the presence and absence of 16K hPRL
(Figure 3D–E). Each cell type was placed in one of two wells made
1 mm apart, the HBVP were allowed to migrate for 72 h, and
their migration distance was measured. HBVP cultured in the
16K PRL on Notch Signaling and Vessel Maturation
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absence of HUVEC exhibited a pattern of random movement,
migrating uniformly from all edges of the circle. When HBVP
were cocultured with HUVEC for 72 h, they migrated towards the
HUVEC in a directional manner. In the presence of 16K hPRL,
the HBVP migration distance was about 50% shorter than in its
absence. These results indicate that 16K hPRL prevents pericyte
recruitment to endothelial cells.
16K hPRL acts specifically on endothelial cells but not on
pericytes
Because the described ex vivo results might be due to direct
effects of 16K hPRL on PC/SMC, we used primary HBVP to
confirm that 16K hPRL acts specifically on endothelial cells.
16K hPRL does not affect HBVP viability, in sharp contrast to
the topoisomerase I inhibitor camptothecin (Figure 4A). In a
BrdU incorporation assay, 16K hPRL treatment does not alter
PDGF-BB-induced HBVP proliferation (Figure 4B). In a
modified Boyden chamber assay, HBVP migration was increased
2.5-fold when the cells were treated with PDGF-BB; but no
direct effect was observed when the HBVP were treated with
16K hPRL (Figure 4C). In contrast, in HUVEC 16K hPRL
induces by 3-fold Caspase-3 activity, one of the most common
events in the apoptosis signaling pathway (Figure 4D). Further-
more, 16K hPRL inhibits bFGF-induced HUVEC proliferation
by 2-fold and migration by 3.5-fold (Figure 4E-F). Together
these results strongly argue against any direct effect of 16K
hPRL on PC/SMC and confirm its specific effect on endothelial
cells.
Figure 1. Inhibition of tumor growth by 16K hPRL is associated with an increased vessel number but with decreased vessel
perfusion. (A) The data represent mean tumor volumes 6 SEM in 16K-Ad-treated (n = 8) or Null-Ad-treated (n = 10) mice. (B) The number of tumor
vessels per field 6 SEM was determined on CD31-positive vessels in x100 power fields of each section. Bar, 100 mm. (C) Representative photographs
of tumor sections from 16K-Ad- and Null-Ad-inoculated mice, double-stained for the endothelial cell marker CD31 (red) and the perfusion marker
lectin (green). White arrows, vessels stained positive for CD31 and lectin. Heads of white arrows, vessels only positive for CD31. (D) The perfusion
index was calculated as the percentage of lectin-positive vessels (perfused vessels) per CD31-positive vessels in the B16F10 tumors6 SEM. For (B) and
(D) the data represent, for each set of conditions, the mean ratio 6 SEM calculated for all the fields of all tumor sections (one section per tumor). *,
P,0.05.
doi:10.1371/journal.pone.0027318.g001
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16K hPRL inhibits Notch-related gene expression in
endothelial cells and pericytes
Having observed modified expression of PDGF-B, angiopoie-
tins, Dll4, and EphrinB2 in tumors of 16K hPRL-treated mice, we
figured that 16K hPRL might disturb vessel maturation by
interfering with the corresponding signaling pathways. To get a
clearer picture of the molecular components of endothelial cell-
pericyte interaction and of how 16K hPRL affects them, we
cultured HUVEC and HBVP alone or together, in the presence or
absence of 16K hPRL for 6 h or 16 h. We then separated the
Figure 2. Reduced pericyte coverage in B16F10 tumor vessels after 16K-Ad treatment. (A) Representative photographs of 80 mm thick
tumor sections from 16K-Ad- and Null-Ad-inoculated mice, double-stained for the endothelial cell marker CD31 (green) and the mural cell markers a-
SMA, desmin, and NG2 (red). (B) Computer-assisted image analysis was used to quantify pericyte coverage. The area occupied by vessels and the
covered area were estimated. Coverage was calculated by dividing the latter area by the former. The data represent, for each set of conditions, the
mean ratio6 SEM calculated for all the fields of all tumor sections (one section per tumor). We analyzed 10 tumors of Null-Ad-treated and 8 tumors of
16K-Ad-treated mice. Bar, 100 mm. (C) Representative photographs of tracheal capillaries. Tracheal capillaries from 16K-Ad- and Null-Ad-inoculated
mice were visualized by lectin-FITC staining (green) and pericytes were visualized by desmin immunostaining (red). Bar, 25 mm. (D) Computer-assisted
image analysis was used to quantify pericyte density. (E) RNAs were extracted from tumors and the relative abundance 6 SEM of each specified
mRNA (encoding pdgf-b, Ang1, or Ang2) was assessed by qRT-PCR in 10 Null-Ad tumors and 8 16K-Ad tumors. (F) Western blot analysis of Dll4 and
(G) EphrinB2 in different 16K-Ad-treated and control tumors. n.s., non significant. *, P,0.05. **, P,0.001. ***, P,0.0001.
doi:10.1371/journal.pone.0027318.g002
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endothelial cells from the pericytes with endothelial-cell-specific
anti-CD31-conjugated beads. To verify that the isolated cell
populations have been successfully purified, we performed
immunostaining for specific endothelial cell vs pericyte markers
before and after cell separation. For both cell types, we did not
observe any significant cross contamination (Figure 5A).
We then examined the expression of various markers in the
individual cell populations. We first measured ANG2 and PDGFB
transcript levels in HUVEC and ANG1 and PDGFR-B transcript
levels in HBVP by qRT-PCR. 16K hPRL treatment was not
found to have any effect on ANG2, PDGFB and ANG1 levels,
whether the two cell types were cultured alone or together
(Figure 5B–E). Interestingly, 16K hPRL reduced the level of
PDGFR-B mRNA in HBVP but only when these cells were
cultured with HUVEC (Figure 5E).
To assess the effect of 16K hPRL on Notch signaling, we
focused on transcript-level expression of DLL4, the Dll4 receptors
NOTCH1 and NOTCH4, and their target genes HEY2 and
EPHRINB2. In HUVEC, Notch signaling was activated by
coculturing with HBVP, as judged by the increased levels of
DLL4, NOTCH1, NOTCH4, HEY2 and EPHRINB2 transcripts
(Figure 6A–E). Consistent with this, we observed an elevated level
of the intracellular domain of the Notch 1 receptor (Notch1 ICD)
which confirms that Notch1 signaling pathway is activated upon
coculture of HUVEC and HBVP (Figure 6F). A 6h-treatment with
16K hPRL decreased the levels of DLL4, NOTCH4, HEY2 and
EPHRINB2 transcripts in HUVEC cultured alone or with HBVP
(Figure 6A, B, D and E) but did not reduce the level of NOTCH1
mRNA or Notch1 ICD protein (Figure 6C).
In pericytes, Notch3 also contributes to vessel stabilization
through cell-cell contact. Dll1 produced by endothelial cells
activates Notch3 on mural cells, thereby promoting mural-cell
maturation [24]. In addition, Jagged1 expressed by endothelial
cells specifically activates Notch3 in mural cells and this activity is
both necessary and sufficient for the expression of smooth muscle
genes. Activated Notch3 can promote its own expression as well as
the one of its ligand Jagged1 in the same cell [23]. Accordingly,
HBVP cocultured with HUVEC produced higher levels of both
NOTCH3 and aSMA (smooth muscle marker) transcripts than did
HBVP cultured alone (Figure 7A and C). Treatment of the
Figure 3. 16K hPRL inhibits pericyte outgrowth in an aortic ring assay and pericyte migration towards endothelial cells. (A)
Photomicrographs of mouse aortic ring cultured in collagen for 9 days and incubated without specific treatment (Ctrl) or under 16K hPRL treatment
(16K). Data representative of at least 2 independent experiments are shown. Bar, 1 mm. (B) Quantification of migrating cell distribution around the
aortic ring performed by computerized image analysis. Cell distribution is defined as the number of intersections between spreading cells and a grid
of concentric rings, plotted as a function of the distance to the aortic fragment. Each curve is a mean of the cell network distribution obtained by
averaging at least 5 individual distributions generated for each experimental condition. (C) Photomicrographs of a mouse aortic ring cultured in
collagen for 9 days without specific treatment (Ctrl) or in the presence of 100 nM 16K hPRL. The rings were fixed for subsequent immunostaining:
anti-Isolectin B4 Ab (IB4: green) identifying EC, anti-NG2 proteoglycan Ab (NG2: red) identifying PC/SMC. Nuclei were colored with DAPI (blue). Data
representative of at least 2 independent experiments are shown. Bar, 100 mm. (D) HBVP migration towards HUVEC was assessed in an under-agarose
migration coculture assay. HUVEC were treated for 72 h with 100 nM 16K hPRL (16K). d =migration distance between the beginning (solid line) and
the end of the migration (dotted line). *, P,0.05.
doi:10.1371/journal.pone.0027318.g003
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cocultures with 16K hPRL for 16 h significantly decreased the
NOTCH3 and aSMA transcript levels in these cells (Figure 7A–C).
The decreased level of the Notch3 intracellular domain (Notch3
ICD) detected in pericytes confirms that 16K prolactin reduces the
Notch3 signaling in pericytes cocultured with endothelial cells
(Figure 7B). In endothelial cells, the level of DLL1 transcripts was
higher in the presence of pericytes (Figure 7D). Interestingly, 16K
hPRL treatment caused the DLL1 transcript level to decrease
(Figure 7D). In pericytes and endothelial cells, the level of
JAGGED1 transcripts was higher when they are cocultured
together (respectively Figure 7E and F). 16K hPRL treatment
did not affect the JAGGED1 transcript level in pericytes but
surprisingly increased its level in endothelial cells.
Together, the results of these expression studies suggest that 16K
hPRL affects cell-cell interactions in (co-)cultured endothelial cells
and pericytes, notably by interfering with Notch signaling pathways.
Discussion
We have previously shown in the murine subcutaneous B16-F10
melanoma model that the antiangiogenic factor 16K hPRL
reduces tumor growth, although its administration is paradoxically
associated with an apparent increase in tumor vessel density [13].
Indeed based on the fact that 16K hPRL exerts in vitro its
antiangiogenic effects by inhibiting proliferation and inducing
apoptosis of endothelial cells, 16K hPRL would be expected to
inhibit overall vascular formation. Actually, we previously
reported that even if the vessels density is increased, the size of
the vessels is strongly reduced [13]. So by inhibiting EC
proliferation and inducing their apoptosis, 16K hPRL leads to
an increase of vessels number but with a smaller size. This
observation could, at least in part, be explained by the effect of
16K hPRL on Notch signaling. Indeed previous studies have
shown that tumor treatment with Dll4 inhibitor inhibits tumor
growth by promoting non productive angiogenesis. Indeed this
blockade led to increased tumor vascularity but with reduced
perfusion [32]. Similarly in this study we observed that 16K hPRL
treatment leads to an increased vessel number but the vessel
perfusion is reduced.
Furthermore, the tumor blood vessels observed after treatment
(contrarily to other vessels) displayed reduced coverage by
pericytes. This is a sign that the vessels failed to mature properly.
Our data thus suggest that 16K hPRL treatment prevents the
development of a normally functioning tumor vasculature by
Figure 4. Endothelial cell specific effect of 16K hPRL. The response of human brain vascular pericytes (HBVP) and human umbilical vein
endothelial cells (HUVEC) to 16K hPRL was examined. (A) HBVP viability was evaluated by means of the calcein assay. 16K: 100 nM 16K hPRL. Cam:
camptothecin-treated cells, a positive control. Rlu: relative luminescence units. Each bar represents a mean 6 SEM, n = 3. Two different experiments
were performed. (B) HBVP were treated with 20 ng/ml PDGF-BB to stimulate proliferation and 100 nM 16K hPRL (16K). HBVP proliferation was
assayed 48 h later by measuring BrdU incorporation. The data presented are means 6 SEM, n = 5 and are representative of at least two independent
experiments. (C) HBVP migration was assessed in a modified Boyden chamber (Costar, Corning Inc.). HBVP were treated for 17 h with 20 ng/ml PDGF-
BB to stimulate migration and 100 nM 16K hPRL (16K). The data presented are means 6 SEM, n = 3 and are representative of at least two
independent experiments. (D) Apoptosis in HUVEC was assessed by quantification of Caspase-3 activity. HUVEC were treated for 16h with 50 nM 16K
hPRL. (E) HUVEC were treated with 10 ng/ml bFGF to stimulate proliferation and 100 nM 16K hPRL (16K). HUVEC proliferation was assayed 24 h later
by measuring BrdU incorporation. The data presented are means 6 SEM, n = 5 and are representative of at least two independent experiments. (F)
HUVEC migration in a scratch-wound assay 8 h after treatment with bFGF and VEGFA and with or without 50 nM 16K hPRL. The data presented are
means 6 SEM, 5 measurements/condition, n = 3 and are representative of at least two independent experiments. n.s., non significant.*, P,0.05. **,
P,0.001. ***, P,0.0001.
doi:10.1371/journal.pone.0027318.g004
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impairing vessel maturation. Our observations are in line with
several studies on tumor vessel maturation in mouse models,
where reduced pericyte recruitment is associated with increased
vessel density but decreased tumor vessel perfusion [33,34,35]. In
such situations, reduced pericyte recruitment may contribute to
excessive vessel sprouting. The result is a highly chaotic vascular
network lacking the hierarchy essential to efficient directional
blood flow.
Further evidence that 16K hPRL affects vessel maturation relies
on the ability of 16K hPRL to inhibit outgrowth of a pericyte/
smooth muscle cell network ex vivo and pericyte recruitment to
endothelial cells in vitro. These effects on pericyte behavior appear
to be indirect, since 16K hPRL shows no toxicity towards these
cells and does not inhibit their proliferation or ability to migrate.
Various pathways and factors involved in pericyte recruitment
during embryonic development have also been linked to tumor
Figure 5. Decreased expression of PDGFR-B in HBVP cocultured with HUVEC after 16K hPRL treatment. A. CD31 (endothelial cells) and
a-SMA(pericytes) immunohistochemistry on HUVEC and HBVP cells before and after separation with MACS. (B-E) HUVEC pretreated for 30 min with
100 nM 16K hPRL (16K) were cultured for 16 h in the presence or absence of HBVP. The two cell populations were then separated prior to qRT-PCR
analysis and subjected to qRT-PCR analysis to detect ANG2, ANG1, PDGFB and PDGFR-B transcripts. Data are presented as means6 SEM, n= 3 and are
representative of at least two different experiments. n.s., non significant. *, P,0.05.
doi:10.1371/journal.pone.0027318.g005
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angiogenesis. One of these factors is PDGF-B. Tumors engineered
to overexpress PDGF-B show an increased coverage of blood vessels
by pericytes [36,37]. Inhibition of PDGFR-B signaling can loosen,
detach, or even eliminate pericytes from the tumor vessels [38]. The
role of the development-related factors Ang1 and Ang2 in tumor-
associated angiogenesis remains controversial. Blood vessel stabili-
zation by Ang1 might either promote tumor angiogenesis or reduce
tumor growth depending on the tumor model [20]. Ang2 is an
antagonist of Ang1. It is only weakly expressed in endothelial cells
under physiological conditions, but its expression is dramatically
increased during vascular remodeling, e.g., during tumor growth.
Increased levels of Ang2 in the tumor endothelium have been
shown to result in aberrant vessels with poor smooth muscle cell
coverage [20]. We observed reduced PDGF-B and ANG1 expression
and increased ANG2 expression in the tumors of 16K hPRL-treated
animals. This, according to the literature, strengthens our
hypothesis that 16K hPRL restricts tumor vessel maturation. Yet
we observed no transcript-level deregulation of these factors in our
in vitro cocultures. This may be due to the fact that culture conditions
do not perfectly mimic the in vivo tumor microenvironment, but we
cannot exclude a contribution of the tumor compartment to the
mRNA levels measured in whole tumor tissue. However, we
observed a reduced PDGFR-B expression in pericytes cocultured
with endothelial cells after 16K hPRL treatment.
Figure 6. Decreased expression of Notch factors in HUVEC cocultured with HBVP after 16K hPRL treatment. (A–E) HUVEC pretreated
for 30 min with 100 nM 16K hPRL (16K) were cultured for 6 h in the presence or absence of HBVP. The two cell populations were then separated prior
to qRT-PCR analysis and subjected to qRT-PCR analysis to detect DLL4, NOTCH4, NOTCH1, HEY2 and EPHRINB2 transcripts. (F) Western blot analysis to
detect Notch1 ICD. Data are presented as means 6 SEM, n = 3 and are representative of at least two different experiments. n.s., non significant. *,
P,0.05; ***, P,0.0001.
doi:10.1371/journal.pone.0027318.g006
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In addition to the above-mentioned paracrine factors, molecules
involved in direct cell-cell contact are also essential to vessel
maturation. Recently, the Notch signaling pathway has emerged
as indispensable to vessel maturation through its role in pericyte
recruitment and cell-cell-contact-mediated differentiation [17].
We therefore hypothesized that disruption of the Notch signaling
pathway might contribute to explaining our results. In support of
this hypothesis, we show that in endothelial cells cultured alone or
with pericytes, 16K hPRL decreases expression of the ligand Dll4,
its receptor Notch4, and the target genes Hey2. Furthermore, Dll4
expression is diminished in tumors after 16K hPRL treatment.
These results are in line with those of Scehnet et al., who
demonstrated decreased growth of S180 tumors and defective
maturation of tumor vessels in response to inhibition of Dll4
signaling. In their work, the tumor vessels displayed a small
caliber, a reduced vessel lumen, markedly reduced pericyte
recruitment, and deficient vascular perfusion [35]. This is precisely
the phenotype that we have observed here. In addition, Real and
collaborators have recently showed that transplantation of bone
marrow-derived vascular precursor cells with decreased Dll4 into
Figure 7. Decreased expression of Notch factors in HUVEC-HBVP cocultures after 16K hPRL treatment. In cultures of HBVP or HUVEC
alone, the cells were treated with 100 nM 16K hPRL (16K) for 16 h. HBVP+HUVEC cocultures were seeded and treated as in Fig. 6, but the time spent
in coculture was longer (16 h). The two cell populations were then separated prior to qRT-PCR analysis. In HBVP, transcripts of NOTCH3 and aSMA
were detected (respectively A and C). Western blot analysis was also performed to detect Notch3 ICD (B). In HUVEC, DLL1 transcripts were detected
(D). In HBVP and HUVEC, JAGGED1 transcripts were detected (respectively E and F). The presented data are means6 SEM, n= 3 and are representative
of at least two independent experiments. n.s., non significant. ***, P,0.0001.
doi:10.1371/journal.pone.0027318.g007
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tumor-bearing mice resulted in the formation of unstable vessels,
as evidenced by the reduced pericyte coverage and reduced
Fibronectin expression [39]. This led to a decreased tumor growth.
All this supports the above hypothesis.
Recently, an essential role in post-natal assembly of pericytes
with endothelial cells has been attributed to EphrinB2, which also
plays a crucial role in non-productive angiogenesis caused by a
Dll4 blockade [28,40]. Interestingly, we show that EphrinB2
expression is decreased by 16K hPRL both in 16K-Ad-treated
tumors and in endothelial cells cultured alone or with pericytes.
These data suggest that an angiogenesis inhibitor like 16K hPRL
can impair the assembly of pericytes with endothelial cells by
perturbing Dll4/Notch4 crosstalk and EphrinB2 expression (see
model on figure 8).
Notch signaling is not restricted to endothelial cells. Pericytes and
vascular smooth muscle cells express mainly the receptor Notch3, a
key player in vessel maturation [22]. Here, we show that coculturing
with endothelial cells increases NOTCH3 and aSMA expression in
pericytes. Conversely, we have measured the level of transcripts
encoding Dll1, a ligand of Notch3, in cultured endothelial cells,
showing that it rises in response to coculturing with pericytes. These
results are in agreement with a recent study showing that endothelial
cells induce mural cell differentiation through activation and
induction of Notch3 [23]. Interestingly, 16K hPRL treatment caused
reduced DLL1 expression in endothelial cells and reduced NOTCH3,
NOTCH3 ICD and aSMA expression in pericytes cocutured with
endothelial cells. Since 16K PRL does not act directly on pericytes,
our results suggest that the reduced expression of Dll1 by 16K hPRL
in endothelial cell would lead to a decrease in the expression of the
Notch3 receptor in pericytes. Consequently the Notch3 signaling is
reduced in pericytes resulting in a decrease level of smooth muscle
gene transcription in these cells (see model on Figure 8). These results
suggest that 16K hPRL can hinder the differentiation of pericytes
which may be responsible of the reduced pericytes coverage of blood
vessels observed in tumors treated by 16K hPRL.
The regulation by 16K hPRL of another Notch ligand Jagged1 is
interesting. As previously shown by others, we observed that
JAGGED1 levels are elevated when pericytes are cocultured with
endothelial cells [21]. Surprisingly, JAGGED1 levels are increased in
endothelial cell following 16K hPRL treatment. Although this could
appear paradoxical, this type of regulation has previously been
observed for other factors. For example, TNF-alpha decreased Dll4
expression in endothelial cells while increased Jagged1 expression
[41]. This observation is consistent with the opposite effects of Dll4
and Jagged1 in angiogenesis previously reported [41].
The mechanisms by which 16K hPRL acts on the above-
mentioned vessel-maturation-related factors and pathways are
under investigation. At present, we know that 16K hPRL inhibits
VEGF-induced Ras activation, thereby blocking MAPK activation
and abolishes bFGF-stimulated growth of cultured endothelial
cells. Interestingly, VEGF enhances PDGFB expression [42], and
VEGF and bFGF are positive regulators of Dll4 and EphrinB2
expression in endothelial cells [43]. We might thus speculate that
inhibition of VEGF and bFGF signaling by 16K hPRL leads to
inefficient activation of the PDGF-B/PDGFR-B, Ang/Tie2, and
Dll4/Notch pathways. In addition, as Dll4 signaling from
endothelial cells to Notch-expressing mural cells upregulates
PDGFR-B expression [44], we might speculate that 16K hPRL
by regulating Dll4 expression affects PDGFR-B signaling and
thereby inhibits vessel maturation. We might also speculate that
16K hPRL affects the Delta/Notch pathway by regulating NF-kB,
since 16K hPRL has been shown to activate NF-kB in endothelial
cells [6] and since complex cross-talk between NF-kB and Notch
has been described at multiple levels in vertebrate systems [45].
To date, four angiogenesis inhibitors have been approved for
cancer treatment by the U.S. Food and Drug Administration [46]:
bevacizumab, sorafenib, sunitinib, and thalidomide. These anti-
angiogenic drugs that disrupt VEGF signaling, induce a transient
functional normalization of the tumor vasculature (immature vessels
are pruned, blood vessel tortuosity decreases, and a closer
association between pericytes and endothelial cells is induced) that
can improve the activity of coadministered chemotherapies or the
effect of radiation therapy [47,48]. Molecularly, VEGF inhibition
causes vessel normalization in part by the upregulation of Ang1 and
by the activation of the PDGFR-B signaling that enhance pericyte
coverage of the vessels [44]. Our data suggest that 16K hPRL does
Figure 8. Hypothetical model of 16K hPRL effects on Notch signaling in endothelial/pericyte interactions. When endothelial cells are
cultured with pericytes, Dll4/Notch4 pathway is activated. 16K hPRL treatment (6 h) alters Dll4/Notch4 signaling by decreasing DLL4, NOTCH4, HEY2
and EPHRINB2 transcripts in endothelial cells. After 16 h of endothelial cell-pericyte cocultures, Notch3 and Dll1 are increased respectively in pericytes
and endothelial cells. 16K hPRL inhibits the Dll1/Notch3 signaling by reducing DLL1 transcripts in endothelial cells and NOTCH3 and aSMA transcripts
in pericytes.
doi:10.1371/journal.pone.0027318.g008
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the opposite. This is quite interesting in the light of the fact that
protection of the tumor vasculature by increased pericyte coverage
is one of emerging mechanisms of evasive resistance to antiangio-
genic therapies [49]. Recently, Helfrich et al. have shown that tumor
vessels resistant to anti-VEGF therapy are characterized by an
enhanced vessel diameter and by normalization of the vascular bed
by coverage with mature pericytes [50]. Clinical trials are underway
to determine whether it is preferable to inhibit a single pathway (and
cause transient normalization) or to combine VEGF inhibitors with
agents that disturb vascular ‘‘normalization’’ by disrupting pericyte
support [49]. Activation of the Notch ligand/receptor system plays
an important role in the development of resistance to antiangiogenic
therapy due to increased vessel maturation and normalization [46].
Tumors with intrinsic resistance to anti-VEGF agents appear to be
sensitive to inhibition of Dll4 [46,51]. The association between Dll4
and tumor resistance to anti-VEGF inhibition suggests that
targeting Notch factors in addition to VEGF may prove to be of
greater therapeutic effect [51].
Here, we show that the antiangiogenic agent 16K hPRL impairs
tumor vessel maturation by reducing activation of the Notch
ligand/receptor pathway. This is the first time, to our knowledge,
that an endogenous antiangiogenic compound is described to
inhibit Notch signaling in endothelial cells and pericytes. In the light
of all these data, 16K hPRL appears as a very promising agent for
future antiangiogenic cancer therapy with a lesser likelihood of
treatment resistance linked to vessel maturation and stabilization.
Materials and Methods
Ethics Statement
The human endothelial cells used in this study were generated
from umbilical cords obtained of women donors after delivery. A
written informed consent was obtained from each individual. The
human protocols were approved in accordance to legal provision
by the Ethics Committee of the ‘‘Centre Hospitalier Re´gional
Citadelle’’. All animal experiment protocols were approved by the
Institutional Animal Ethics Committee of the University of Lie`ge
under application number 941.
Production of recombinant proteins
Recombinant 16K hPRL was produced in E. coli as previously
described [6]. The purity of the recombinant protein exceeded
95% (as estimated by Coomassie blue staining) and the endotoxin
level was 0.0005 ng/ng recombinant protein, as quantified with
the rapid endo test of the European Endotoxin Testing Service
(BioWhittaker, Verviers, Belgium).
Adenovirus vectors
16K-Ad is a defective recombinant E1-E3-deleted adenovirus
vector encoding a secreted peptide consisting of the first 139 amino
acids of PRL. This adenovirus vector was constructed as described
[10], using the Adeno-X expression system (BD Biosciences,
Erembodegem, Belgium). Purification and titration of the recombi-
nant adenoviruses were performed respectively with the BD Adeno-
X Virus Purification kit (BD Biosciences, Erembodegem, Belgium)
and the Adeno-X Rapid Titer kit (BD Biosciences, Erembodegem,
Belgium), according to the manufacturer’s instructions. Null-Ad is a
control adenovirus carrying an empty expression cassette.
Quantitative real time-polymerase chain reaction (qRT-PCR)
Total RNAwas isolated with the RNeasy mini kit (Qiagen, Venlo,
Netherlands) or the Nucleospin RNA/Protein kit (Macherey-Nagel
GmbH, Dueren, Germany) and reverse transcribed with the iScript
cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) to generate
cDNA. Quantitative PCR was performed using a one-step system
(Applied Biosytems, Carlsbad, CA, USA) with Faststart Universal
SYBR Green Master (Roche, Clinical Laboratories, Indianapolis,
IN, USA). The fold difference for various transcripts was calculated
by the DDCT method using cyclophilin A (PPIA) as the internal
control. The following primers were used for qRT-PCR: human
ANG1 forward (59-CTCGCTGCCATTCTGACTCAC-39), re-
verse (59-GACAGTTGCCATCGTGTTCTG-39); murine ANG1
forward (59-CTCAGTGGCTGCAAAAACTTGA-39), reverse (59-
TGGCCGTGTGGTTTTGAAC-39); human ANG2 forward (59-
TAAGCAGCATCAGCCAACCAG-39), reverse (59-AAACCAC-
CAGCCTCCTGTTAGC39-); murine ANG2 forward (59-AC-
CTTCAGAGACTGTGCGGAAA-39), reverse (59-CGTCCATG-
TCACAGTAGGCCTT-39); murine PDGFB forward (59-CCA-
TCCGCTCCTTTGATGAT-39), reverse (59-TCAGCCCCATC-
TTCATCTACG-39); human PDGFB forward (59-AACAACCG-
CAACGTGCAGT-39), reverse (59-GTCACCGTGGCCTTCT-
TAAAGA-39); human PDGFR-B forward (59-AGACACGGGA-
GAATACTTTTGC-39); reverse (59-AGTTCCTCGGCATC-
ATTAGGG-39); human Jagged1 forward (59-TGGGCTTTGA-
GTGTGAGTGT-39); reverse (59-CCCCGTGGGAACAGT-
TATTA-39); human DLL4 forward (59- ACCACTTCGGCCAC-
TATGTGTG -39), reverse (59-AGCCCGAAAGACAGATAGGC-
TG-39); human DLL1 forward (59-ATATGCCCCAACGAA-
TGCTG-39), reverse (59-GCTCGGTCTGAACTCGGTTTC-39);
human Notch1 forward (59-CGGGTCCACCAGTTTGAATG-
39), reverse (59-GTTGTATTGGTTCGGCACCAT-39); human
Notch4 forward (59-CGATAATGCGAGGAAGATACGG-39), re-
verse (59- GATCGGAATGTTGGAGGCA-39); human Notch3
forward (59-CAATGCTGTGGATGAGCTTG-39), reverse (59-
AAGTGGCTTCCACGTTGTTC-39); human HEY2 forward
(59-TGAGTTGAGAAGACTTGTGCCA-39), reverse (59-AAGT-
AGCCTTTACCCCCTGTTG-39); human EphrinB2 forward (59-
CGTGCTGGAGAATTGACTGA-39), reverse (59-CTGTCT-
TCCCTTGGCTTCTG-39); human aSMA forward (59-CAAGT-
GATCACCATCGGAAATG-39), reverse (59-GACTCCATCCC-
GATGAAGGA-39); murine PPIA forward (59-ACCGTGTTCT-
TCGACATCACG-39), reverse (59-CTGGCACATGAATCCTG-
GAATA-39); human PPIA forward (59-CCAACACAAATGGTT-
CCCAGT-39), reverse (59-CCATGGCCTCCACAATATTCA-39).
Mice
Adult female C57BL/6J mice (6–8 weeks of age) purchased
from the Central Animal Facility of CHU Lie`ge (Lie`ge, Belgium)
were used to assess tumor growth.
In vivo tumorigenicity
C57BL/6 mice were i.v. inoculated with either 109 pfu Null-Ad or
109 pfu 16K-Ad adenovirus vector. Two days later, mice were s.c.
injected with 105 B16-F10 mouse melanoma cells. Adenovirus vector
injection was repeated once, one week after the first inoculation.
Fifteen days after tumor inoculation, the mice were sacrificed and
their tumors harvested. Tumor volumes were measured every one or
two days and calculated as follows: length x width260.5 [52].
Evaluation of vessel perfusion
To mark vessel perfusion, tumor-bearing mice were i.v. injected
with FITC-Lycopersicon esculentum lectin in 0.9% NaCl (100 mg,
Vector Laboratories, Burlingame, CA, USA) 3 minutes before
sacrifice and perfused with 1% paraformaldehyde (PFA). Tissues
were removed, postfixed in 1% PFA for 1 hour at 4uC, incubated
overnight in 30% sucrose, and snap frozen. A perfusion index was
quantified as the percentage of lectin-positive vessels per CD31-
positive vessels in the B16F10 tumors.
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Tracheal analysis
Before sacrifice, mice were injected with FITC-Lycopersicon
esculentum lectin and perfused with 1% PFA. Tracheas were
removed, immersed in fixative for one hour, and stained as whole
mounts. Pericytes were stained with rabbit anti-mouse desmin
(clone Y66, 1:1000, Millipore, Bedford, MA, USA) followed by a
secondary Cy3-conjugated antibody (Jackson ImmunoResearch,
West Grove, PA, USA). Digital images were acquired with a
fluorescence microscope (Eclipse 90i, Nikon Belux, Bruxelles,
Belgium). The pericyte density in the cartilaginous region
(capillary region) was measured in at least 5 regions per animal
with ImageJ software (http://rsbweb.nih.gov/ij/).
Immunohistochemistry
To assess vessel maturation, frozen tumor sections (6–80-mm
thick) were fixed in acetone (VWR, Leuven, Belgium) for 30 min
at 4uC. Next, the sections were incubated with a rat monoclonal
anti-CD31 (1/250, BD Biosciences, Erembodegem, Belgium) for
2.5 h, followed by a biotinylated donkey anti-rat secondary
antibody (1/100, Jackson immunoresearch, Suffolk, UK) and
finally by streptavidin/Cy5 complex (1/150, Jackson Immunor-
esearch, Suffolk, UK) for 1.5 h at room temperature. These
CD31-positive sections were incubated for 2.5 h at room
temperature with Cy3-conjugated mouse monoclonal anti-aSMA
(1/1500, Sigma-Aldrich, Bornem, Belgium) or with rabbit
polyclonal anti-desmin (1/1000, Abcam, Cambridge, UK) or
rabbit polyclonal anti-NG2 (1/200, Millipore, Bedford, MA, USA)
followed by incubation with goat anti-rabbit IgG-Cy3 (1/500,
Jackson Immunoresearch, Suffolk, UK) for 1.5 h at room
temperature. To verify that the isolated cell populations have
been successfully purified, we performed immunostaining for
specific endothelial cell vs pericyte markers before and after cell
separation. After separation, cells were seeded on coverslips. After
24 h, cells were fixed for 30 min with 1% PFA in PBS and
incubated with the blocking solution (20% FBS, 1% BSA) for
15 min. Cells were then incubated with a mouse anti-human
CD31 (1/50, BD Biosciences, Erembodegem, Belgium) or with a
mouse anti-human a-Smooth Muscle Actin (1/50, Sigma-Aldrich,
Bornem, Belgium) for 1 h, followed by incubation with a
biotinylated polyclonal goat anti-mouse antibody (1/50, Jackson
immunoresearch, Suffolk, UK) and with a streptavidin-PE
antibody (1/50, Jackson immunoresearch, Suffolk, UK). The
samples were mounted with Prolong (Invitrogen Corp./Life
Technologies, Paisley, Scotland). All immunohistochemical stain-
ings were examined with a standard fluorescence microscope (90i
Eclipse, Nikon Belux, Bruxelles, Belgium).
Image processing and measurement of tumor pericyte
coverage
Gray level images of vessels and covered regions were binarized
automatically using the entropy of the histogram of gray level
intensities [53]. On the binarized images obtained, the area
occupied by vessels and the covered area were estimated.
Coverage was calculated by dividing the latter area by the former.
At least 15 images per tumor were analyzed. For statistical
analysis, the unpaired Wilcoxon test was used to compare the
Null-Ad- and 16K-AD-treated groups. Results were considered
significant at P,0.05.
Ex vivo aortic ring assay
Mouse aortic rings were cultured in three-dimensional type I
collagen gels as previously described [54,55]. Effects of different
compounds were tested by adding them to the culture medium on
day 0. For quantification, computerized image analysis was
performed on a Sun SPARC30 workstation with the Visilog 5.0
(Noesis) software according to Blacher et al.[56]. A grid of
concentric rings is used to determine the number of intersections
with sprouting cells. Results are expressed as number of
intersections plotted as a function of the distance to the ring.
Aortic ring whole-mount immunostaining
On day 9 of culture, aortic fragments embedded in collagen gels
were washed in PBS and fixed in 4% PFA. Nonspecific antibody
binding was blocked with 1.5% milk after washing in PBS.
Samples were incubated overnight at room temperature with a
mix of lectin and primary antibody: Griffonia Simplifolia isolectin-
B4/Alexa Fluor 488 at 5 mg/ml (I21411, Invitrogen Corp./Life
Technologies, Paisley, Scotland) and rabbit anti-NG2 chondroitin
sulfate proteoglycan antibody (AB5320, Millipore, Bedford, MA,
USA) at 10 mg/ml. After washing with PBS, the tissues were
incubated at room temperature with a secondary biotinylated
goat anti-rabbit antibody (E432, Dako, Glostrub, Denmark) at
1.9 mg/ml. This was followed by a 1-h incubation with 1 mg/ml
streptavidin-Cy3 (S6402, Sigma-Aldrich, Bornem, Belgium).
Samples were mounted in Vectashield-Dapi mounting medium
(H-1200, Vector Laboratories, Burlingame, CA, USA).
Cell cultures
HUVEC (Human Umbilical Vein Endothelial Cells) were
isolated as previously described [57]. They were cultured in EBM2
supplemented with 5% FCS and the EGM-2 bullet kit at 37uC in a
5% CO2 humid atmosphere (Lonza, Walkersville, MD, USA).
HBVP (Human Brain Vascular Pericyte) cells were purchased
from Sciencell research laboratories (Sciencell research laborato-
ries, Carlsbad, CA, USA) and cultured in PM (pericyte medium)
supplemented with 2% FCS, 10% pericyte growth supplement
and 100 units/ml penicillin, 100 mg/ml streptomycin at 37uC in a
5% CO2 humid atmosphere (Sciencell research laboratories,
Carlsbad, CA, USA). B16-F10 mouse melanoma cells were
obtained from the American Type Culture Collection (ATCC
CRL-6475, Rockville, Md, USA) and cultured in high-glucose
DMEM supplemented with 10% FCS and 4 mM glutamine,
100 units/ml penicillin, 100 mg/ml streptomycin at 37uC in a
humid 5% CO2 atmosphere (Invitrogen Corp./Life Technologies,
Paisley, Scotland).
Under-agarose migration assay
Endothelial cells and pericytes were plated in two 5-mm wells
created 1 mm apart in 1% agarose/1% FCS in EBM2. Twenty
thousand HUVEC were plated in one well in 25 ml EBM2 with
1% FCS. After 3 hours the HUVEC were treated with 100 nM
16K hPRL, and 30 min later HBVP (26104 cells in the same
medium) were added to the other well. The HUVEC and HBVP
were incubated for 72 h. The cells were then fixed with 2% PFA in
PBS for 30 min and stained with 1% Coomassie blue overnight.
The distance of HBVP migration towards the HUVEC was
measured with ImageJ software. The experiments were performed
in duplicate and the data for statistical analyses were taken from
three independent sets of experiments.
Viability assay
HBVP cells were plated at a density of 26104 cells per well (in
24-well plates) in 0.5 ml pericyte medium. The cells were treated
with 100 nM 16K hPRL or 10 mM campthotecin (Sigma-Aldrich,
Bornem, Belgium) for 72 h. After washing with PBS and
incubation with 1 mM calcein-AM (Calbiochem, Nottingham,
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UK) for 30 min at RT, cell fluorescence was measured at 535 nm
with a microplate reader (Wallac Victor2, Perkin Elmer, Norwalk,
Finland).
Caspase-3 activity assay
HUVEC were plated in 48-well culture plates at a density of
506103 cells per well in 500 ml of culture medium. After 48 h
incubation, the cells were treated with 50 nM hPRL 16K.
Caspase-3 activity was measured 16 h post-treatment with the
CaspACE Assay System Fluorimetric (Promega Corp., Madison,
WI) according to the manufacturer’s instructions.
Proliferation assay
HBVP were plated in 96-well culture plates at a density of
26103 per well in pericyte medium. After overnight incubation,
the culture medium was replaced with fresh medium containing
0.5% FCS and incubated for 24 h. The medium was then
replaced with serum-free pericyte medium and the cells were
stimulated with 20 ng/ml PDGF-BB (R&D Systems Europe Ltd,
Oxon, UK) in the presence or absence of 100 nM 16K hPRL.
Proliferation was analyzed 48 h later by measuring BrdU
incorporation with the Cell Proliferation ELISA, BrdU (Colori-
metric) (Roche Clinical Laboratories, Indianapolis, USA). HU-
VEC were plated in 96-well culture plates at a density of 76103
per well in their culture medium. After 48 h incubation, the cells
were stimulated with 10 ng/ml bFGF (Promega Corp.) in the
presence or absence of 50 nM 16K hPRL. Proliferation was
analyzed 24 h later by measuring BrdU incorporation with the
Cell Proliferation ELISA, BrdU (Colorimetric) (Roche Clinical
Laboratories, Indianapolis, USA).
Modified Boyden chamber migration assay
HBVP cell migration was assessed by means of a modified
Boyden chamber assay. Polycarbonate filters (8 mm pore) from
TranswellH (Costar Corp, Cambridge, MA.) were treated
overnight at room temperature with 1% gelatin. The cells were
trypsinized, resuspended in serum-free medium containing 0.1%
BSA, and placed in the upper compartment of the chamber
(806103 cells/filter). The lower compartment of the chamber was
filled with medium containing 1% FCS and 1% BSA, supple-
mented with 20 ng/ml PDGF-BB in the presence or absence of
100 nM 16K hPRL. After incubation at 37uC for 17 h, the filters
were fixed in methanol. Cells on the filters were stained with 4%
Giemsa solution (Fluka Chemika, Buchs, Germany). Cells that had
not migrated, at the upper surface of the filters, were wiped away
with a cotton swab. Migration was quantified by counting the
number of cells on the lower surface of the filters.
Scratch wound migration assay
HUVEC (806103 cells) were seeded into a 48-well plate in
culture medium and incubated for 48 h to reach confluence. With
a tip, a wound was made in the monolayer (at time 0). The cells
were then washed with PBS and stimulated with different media.
To favor migration, cells were incubated for 8 h with medium
containing both 10 ng/ml recombinant bFGF (Promega Corp.)
and 50 ng/ml recombinant VEGFA (RELIATech GmbH) in the
presence or absence of 50 nM 16K hPRL. The distance between
the two sides of the wound was measured with a graduated ocular
lens coupled with an Olympus CKX41 microscope (Olympus).
The distance between the two sides of the wound after 8 h of
migration was divided by the distance at time 0 and represented
on a graph.
Cocultures with direct contact
For 2-dimensional cocultures, 66105 HUVEC were plated in
EBM2 with 1% FCS and 30 ng/ml VEGF in a T25 flask. After
adhesion, 66105 HBVP were added. 16K hPRL was added
30 min prior to the addition of HBVP in the indicated
experiments. To separate the endothelial cells and pericytes,
anti-CD31-conjugated MicroBeads (Miltenyl Biotec GmbH,
Bergisch Gladbach, Germany) were used according to the
manufacturer’s instructions. The separate cell populations were
then processed for western blot analysis or quantitative RT-PCR.
Western blot analysis
Equivalent amounts of proteins from tumor tissues or cells were
resolved by SDS-PAGE and transferred to polyvinylidene fluoride
membranes (Millipore, Bedford, MA, USA). The membranes were
saturated for 1 h in TBS-8% dry milk, then incubated for 1 h with
primary antibodies and for 1 h with secondary antibodies.
Detection was carried out by chemiluminescence with the ECL
Plus kit (Amersham Biosciences, Arlington Heights, IL, USA).
Primary antibodies: DLL4 and NOTCH3 (Santa Cruz Biotech-
nology, Santa Cruz, CA USA), NOTCH1 ICD and EPHRINB2
(Millipore, Bedford, MA, USA), TUBULIN (Abcam, Cambridge,
UK).
Statistical analysis
All data are expressed as means 6 SEM. Analyses for statistical
significance (the Mann-Whitney test) were carried out with Prism
5.0 software (GraphPad Software, San Diego, CA, USA).
Statistical significance was set at P,0.05.
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